title: Role of Colloidal Drug Delivery Carriers in Taxane-mediated Chemotherapy: A Review.
abstract: Chemotherapy is one of the most frequently employed and reliable treatment options for the management of a variety of cancers. Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, non-small cell lung cancer and ovarian cancer. Most of the commercial products of taxanes are available as injectables, which are not patient compliant and are associated with frequent side effects like ototoxicity, baldness and neurotoxicity. Most of these concerns are ascribable to the presence of toxic solvents in these commercial formulations, which are used to solubilize these drug(s). However, there have been several attempts to develop toxic solvent free taxane formulations, especially employing novel drug delivery systems (NDDS). These systems have been reported to result in the advancement of anticancer activity, therapeutic index, stability, biocompatibility, tissue or organ targeting, encapsulation capacity, tissue permeability, oral bioavailability, reduced toxicity and reduced incidences of abnormal reactions, sustained and controlled release in comparison to the conventional solvent-based formulations. The review is an attempt to analyze the potential of NDDS-mediated taxane delivery for safer and effective cancer chemotherapy.
authors.forename: Pramod
authors.initials: P
authors.lastname: Kumar
authors.affiliation: Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Rajasthan, India-305817. razakaisar_pharma@yahoo.co.in.
authors.forename: Kaisar
authors.initials: K
authors.lastname: Raza
authors.forename: Lokesh
authors.initials: L
authors.lastname: Kaushik
authors.forename: Ruchi
authors.initials: R
authors.lastname: Malik
authors.forename: Shweta
authors.initials: S
authors.lastname: Arora
authors.forename: Om Prakash
authors.initials: OP
authors.lastname: Katare
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000737:chemistry / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000737:chemistry / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003102:Colloids / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D001952:Bridged-Ring Compounds; D003102:Colloids; D004337:Drug Carriers; D043823:Taxoids; C080625:taxane